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1 Institute of Biotechnology, University of Cambridge, Cambridge, United Kingdom, 2Department of Psychiatry and Psychotherapy, University of
Cologne, Cologne, Germany, 3Department of Biomolecular Medicine, Division of SORA, Faculty of Medicine, Imperial College, London, United
Kingdom
Background. The initial prodromal state of psychosis (IPS) is defined as an early disease stage prior to the onset of overt
psychosis characterized by sub-threshold or more unspecific psychiatric symptoms. Little is known regarding the biochemical
changes during this period. Methodology/Principal Findings. We investigated the metabolic/proteomic profiles of
cerebrospinal fluid (CSF) of first-onset drug naı¨ve paranoid schizophrenia patients (n = 54) and individuals presenting with
initial prodromal symptoms (n = 24), alongside healthy volunteers (n = 70) using proton nuclear magnetic resonance (1H-NMR)
spectroscopy and surface enhanced laser desorption ionization (SELDI) mass spectrometry, respectively. Partial least square
discriminant analysis (PLS-DA) showed that 36%/29% of IPS patients displayed proteomic/metabolic profiles characteristic of
first-onset, drug naı¨ve schizophrenia, i.e., changes in levels of glucose and lactate as well as changes in a VGF-derived peptide
(VGF23-62) and transthyretin protein concentrations. However, only 29% (n = 7) of the investigated IPS patients (who to date
have been followed up for up to three years) have so far received a diagnosis of schizophrenia. The presence of biochemical
alterations in the IPS group did not correlate with the risk to develop schizophrenia. Conclusions/Significance. Our results
imply that schizophrenia-related biochemical disease processes can be traced in CSF of prodromal patients. However, the
biochemical disturbances identified in IPS patients, at least when measured at a single time point, may not be sufficient to
predict clinical outcome.
Citation: Huang JT-J, Leweke FM, Tsang TM, Koethe D, Kranaster L, et al (2007) CSF Metabolic and Proteomic Profiles in Patients Prodromal for
Psychosis. PLoS ONE 2(8): e756. doi:10.1371/journal.pone.0000756
INTRODUCTION
Prior to the onset of frank psychosis, at-risk patients usually present
with non-specific signs and symptoms, including reduced concen-
tration and motivation, depressed mood, sleep disturbances,
anxiety, social withdrawal, suspiciousness, deterioration in social
functioning, and increased irritability [1]. The duration of the
initial prodromal state of psychosis (IPS) is extremely variable,
ranging from a few weeks to several years and is often
indistinguishable from more severe adolescent behavioural
problems. The initial prodrome may thus reflect a vulnerable
period in which deleterious environmental factors may precipitate
the transition from IPS to the onset of overt psychosis and in turn
schizophrenia. This period provides a window of opportunity for
gaining a better understanding of the pathological process of
schizophrenic psychosis as well as early diagnosis and intervention;
especially as strong evidence suggests that early treatment is
associated with a better prognosis [2,3].
Most efforts to elucidate the IPS have to date focused on the
identification of symptomatic alterations in IPS patients to predict
outcome [4–6]. In our recent studies on first onset, drug naı¨ve
paranoid schizophrenia patients we identified significant altera-
tions in the metabolic and proteomic profiles in CSF [7,8]. The
key metabolic changes included elevated glucose levels, reduced
lactate and acetate levels and a decrease in pH [8]. We also found
increased levels of a VGF-derived peptide (VGF23-62 fragment)
and a decrease in transthyretin protein concentrations in our
proteomic profiling studies [7]. In the present study, we
investigated whether the same or similar CSF alterations can also
be traced in patients meeting symptomatic criteria of an IPS.
RESULTS
We employed 1H-NMR spectroscopy-based metabonomics and
SELDI mass spectrometry-based proteomics techniques to in-
vestigate the CSF profiles of 24 patients in IPS alongside 54 first-
onset drug naive schizophrenia patients and 70 matched healthy
volunteers (Table 1). Results of the comparison of first-onset
schizophrenia patients and controls have been published elsewhere
[7,8].
When comparing the metabolic profiles using PLS-DA, we
observed that IPS patients were distributed across, but mainly in-
between, the distinct clusters of first-onset drug naı¨ve schizophre-
nia patients and healthy controls (Figure 1A). The key differen-
tiating metabolites were CSF glucose and lactate levels (Figure 1B).
33% of IPS patients (n = 8) co-clustered with the schizophrenia
group and 50% (n = 12) co-clustered with controls. When
investigating the whole IPS group (n = 24), neither the comparison
between prodromal patients and controls, nor the comparison
between prodromal and first-onset, drug naı¨ve schizophrenia
patients showed a significant difference (data not shown).
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Similarly, we investigated CSF proteomic profiles in 14 IPS
patients, 17 first-onset, drug naı¨ve schizophrenia patients and 40
healthy volunteers using SELDI mass spectrometry (Table 2). CSF
proteomic profiles of prodromal patients again were distributed
across the clusters of controls and schizophrenia patients (Figure 2A).
Among the IPS patients, 36% (n = 5) co-clustered with the
schizophrenia group. The most important factors contributing to
the partial separation between schizophrenia patients and controls
were the VGF23-62 peptide (at m/z = 3,959) and transthyretin
proteins (at m/z = 13.7214.0k) (Figure 2B). Again, these differences
were not statistically significant when the IPS group was compared to
the control or schizophrenia groups, respectively. Interestingly, we
found that the 5 IPS patients whose proteomic profiles showed
schizophrenia-like changes, also showed significant schizophrenia-
like metabolic alterations (Figure 1 and 2). To date IPS patients have
been followed up for three years and 29 % (n = 7) of the 24 IPS
patients have developed schizophrenia within this period. We
examined whether the presence of schizophrenia-like CSF metabolic
and proteomic alterations in prodromal patients could predict
a subsequent transition to overt schizophrenia. However, we did not
observe a correlation between abnormalities in CSF profiles and
subsequent transition to overt schizophrenia (Figure 3).
Based on the above results, we propose that CSF metabolic and
proteomic changes in the initial prodromal state of psychosis
reflect a molecular disturbance associated with psychosis. Howev-
er, the biochemical investigation of CSF at a single time point
during the initial prodrome may not be sufficient to predict clinical
outcome, possibly due to fluctuations/variation of CSF metabolic/
proteomic profiles during the prodromal phase. Future longitudi-
nal studies with multiple assessment times are required to test this
notion.
DISCUSSION
IPS may be a critical window of opportunity for the prevention of
schizophrenia. In the past, studies on IPS patients have pre-
dominantly focused on the identification of psychopathological as
well as, though to a lesser degree, neurocognitive and structural
cerebral changes (e.g.[1,5,9–13]). The present study is the first
attempt to investigate the biochemical processes associated with
the IPS. The specific interest of the present study was to explore
whether schizophrenia-related biomarkers can be identified in IPS
patients and, if this was the case, whether a biomarker signature
can predict the transition from IPS to overt psychosis. Whilst we
found significant changes between controls and first-onset
schizophrenia patients in CSF samples [7,8], no significant
differences were found when comparing IPS patients to controls,
Table 1. Demographic details of subjects in the
metabonomics study
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Healthy
volunteers
(n = 70)
First-onset, drug
naı¨ve schizophrenia
patients (n = 49)
IPS patients
(n = 24)
Age (yrs)* 27.465.9# 27.268.6 24.265.0
Gender&
male 39 39 18
female 31 15 6
#There is no significant difference in age between the control and disease
groups.
*Data are shown in Mean6SD
doi:10.1371/journal.pone.0000756.t001..
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Figure 1. Metabonomic analysis of CSF samples from control subjects, patients suffering an IPS, and first onset, drug-naı¨ve schizophrenic
patients. (A) and (B) PLS-DA scores and variable loadings plots showing a clear separation of CSF samples derived from drug-naı¨ve schizophrenia
patients (red dots) compared to demographically matched controls (black dots) as determined by the 1H-NMR spectroscopy IPS patients are shown
as green triangles. 33% (n= 8) of the IPS patients were found to cluster with the schizophrenia patients (showing similar metabolic alterations). The
key changing metabolic signals are from lactate and glucose resonances as well as a shift in glutamine. The id’s of the five IPS patients who showed
the greatest metabolic disturbances are displayed on the plot. We found that the presence of metabolic disturbances was highly predictive of the
presence of protein abnormalities (see Fig 2).
doi:10.1371/journal.pone.0000756.g001
Table 2. Demographic details of subjects in the SELDI study
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Healthy
volunteers
(n = 40)
First-onset, drug naı¨ve
schizophrenia patients
(n = 17)
IPS patients
(n = 14)
Age (yrs)* 27.363.8 27.667.9 23.965.1
Gender
male 20 10 10
female 20 7 4
*Data are shown as Mean6SD
doi:10.1371/journal.pone.0000756.t002..
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and IPS patients to schizophrenia patients. We found that the
proteomic and metabolic profiles of IPS patients overlapped
substantially with the profiles of healthy volunteers as well as first-
onset schizophrenia patients. This is conceptually not surprising,
as symptoms during the IPS are less persistent and specific (and
may even return to ‘‘normal’’), which could be reflected in the
disease-related biochemical read-outs (Figure 4). These data imply
that metabolic and proteomic alterations in CSF, i.e. increased
glucose and VGF23-62 peptide levels and reduced lactate and
transthyretin levels, are becoming more significant and persistent
during the first episode of overt psychosis.
The pathological significance of the metabolic and proteomic
alterations observed in CSF in first-onset schizophrenia and
approx. 33% of the IPS patients require further investigation. As
the increase in glucose levels coincides with a decrease in lactate
levels in schizophrenia CSF, a possible scenario is that the diseased
Figure 2. Proteomic analyses of CSF samples from control subjects, patients suffering an IPS, and first onset, drug-naı¨ve schizophrenic patients.
(A) and (B) PLS-DA scores and loadings plot showing a differentiation of drug-naı¨ve schizophrenia patients (red dots) from demographically matched
controls (black dots) as determined by SELDI-MS spectra. IPS patients are shown in green triangles. 33% of the IPS patients were found to cluster with
the schizophrenia patients (showing similar protein alterations). The key changing proteins are a VGF23-62 peptide (at m/z = 3,959, red inverted
triangle) and transthyretin proteins (m/z = 13.7214.0k; blue inverted triangle). The id’s of the six IPS patients who showed the greatest protein
disturbances are marked/numbered on the plot. We found that the presence of protein disturbances was highly predictive of the presence of
metabolite abnormalities (see Fig 1).
doi:10.1371/journal.pone.0000756.g002
Figure 3. No clear association was found between clinical outcomes and metabolic/proteomic profiles of patients suffering an IPS. CSF
metabolic and proteomic profiles of IPS patients were analyzed by 1H-NMR spectroscopy and SELDI-MS, respectively. PLS models based on CSF
profiles from controls and first onset schizophrenia patients were built to try to predict the transition of IPS patients to develop overt psychosis. IPS
patients were followed up for up to 3 years. Those IPS patients who went on to develop overt psychosis are labelled in red. There is no clear
association between clinical outcomes and their CSF metabolic (Figure 3A) and proteomic (Figure 3B) profiles at the prodromal phase of psychosis.
doi:10.1371/journal.pone.0000756.g003
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brain utilizes lactate (which is predominantly produced by
astrocytes [14]) instead of glucose as a primary energy source.
This has been suggested in a number of pathological conditions
such as diabetes and prolonged starvation [15,16]. With regards to
the protein/peptide alterations, the increased levels of the VGF23-
62 peptide may indicate an increase in the native (full-length) VGF
protein and/or abnormalities in the processing of the protein
within the brain. Indeed, our previous study showed that VGF
protein expression was increased in half of the investigated
schizophrenia post-mortem brains [7]. VGF is a secreted poly-
peptide that is selectively expressed by neurons and several
endocrine and neuroendocrine tissues (for review [17,18]), and is
transported in dense core vesicles with the VGF-derived processed
peptides being released via a regulated secretory pathway [17,18].
Knockout of the VGF gene in mice generated a lean, hypermet-
abolic, hyperactive phenotype, demonstrating that VGF may
regulate energy balance [19]. The observation of an increase of the
VGF peptide in CSF from schizophrenia patients, therefore, may
point to a hypometabolic state in the schizophrenia brain. On the
other hand, as transthyretin is a thyroid hormone-binding protein
that transports thyroxine from the bloodstream to the brain [20],
the decreased level of transthyretin in CSF could imply
abnormalities in thyroxine transport in brains of schizophrenia
patients. Taken together, our observations indicate that in first
onset schizophrenia (as well as about 33% of the prodromal
patients), the brain may be in a hypo-metabolic state and that the
preferred energy source may be switched to lactate instead of
glucose. Interestingly, a large scale investigation on long-term
antipsychotic treated rats in our laboratory showed that several
antipsychotic drugs increase brain lactate levels (manuscript in
preparation).
A particular interest of the present study was to explore whether
prodromal patients who co-clustered with the schizophrenia group
with regards to their CSF proteomic and metabolic profiles have
a higher risk of developing schizophrenia. Unfortunately, we did
not find an association between the presence of biochemical
changes in IPS patients and the eventual transition to schizophre-
nia. There are several possible explanations for our observations:
(1). CSF proteomic and metabolic profiles may fluctuate depend-
ing on mental/physical state. Thus, measurements from a single
time point (as investigated in this study) are not sufficient. Multiple
measurements may have better prediction power. (2). Predictive
biomarkers may be expressed at very low concentration and the
technologies used in this study may not have been sensitive
enough. Applying more sensitive methods such as LC-MS/MS
may provide a solution. (3). Changes in CSF in the IPS may not be
indicative of the risk of developing schizophrenia, though they
may still correlate with the pathological process of psychosis.
Of the 24 IPS patients included in this study, 29% (n = 7)
developed overt psychosis/schizophrenia within a 3 year follow-up
period in the current study. This observed transition rate is lower
compared to two previous studies. The Cologne Early Recognition
– CER study [4], ascertained an initial cohort of 385 patients with
symptoms of initially prodromal schizophrenia. Of these 160
patients were re-assessed within a mean period of 9.6 years of the
initial assessment. 65% of the 160 patients had developed
schizophrenic psychosis-20 % within one year of the baseline
assessment, 17% within two and 13% within three years, whereas
the transition rate in those who did not report any of these
symptoms was only 18%. Based on the ‘‘ultra high risk’’ (UHR)
criteria of imminent risk of psychosis, the average 12-months
transition rate in untreated patients is 38%, with not much
knowledge as to the rate of transition in the following years [6].
In summary, we found similar alterations in the metabolic and
proteomic CSF profiles in a subgroup of initially prodromal and
first-onset schizophrenia patients. Our results suggest a progression
of distinct biochemical disturbances, which may be intermittent in
the prodromal disease phase. However, as the number of IPS
patients who transgressed to overt psychosis is at present small,
further studies are required. A preferred (and less invasive)
approach would be to identify serum biomarkers for early/
prodromal diagnosis; in that case multiple sampling to increase the
chance of correctly identifying a fluctuating biochemical pertur-
bation is clinically feasible.
Figure 4. A hypothetical model of alterations in the CSF metabonome and proteome observed in the IPS and in the schizophrenia phase. In the
schizophrenia phase, patients have a distinct metabolic and protein/peptide profiles in CSF, i.e. increased glucose and VGF23-62 peptide levels and
reduced lactate and transthyretin protein levels. During the IPS, key biochemical alterations may vary possibly in accordance with ‘‘mental-state’’
fluctuations between mental well being and schizophrenia-like states. During the first episode of overt psychosis, these alterations become more
persistent and significant. For some IPS patients, their conditions may not deteriorate and their CSF proteomic and metabolic profiles may return to
normal.
doi:10.1371/journal.pone.0000756.g004
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METHODS AND MATERIALS
Clinical samples
The Ethical Committee of the Medical Faculty of the University of
Cologne reviewed and approved the protocol of this study and the
procedures for sample collection and analysis. All study partici-
pants gave their written informed consent. All clinical investiga-
tions were conducted according to the principles expressed in the
Declaration of Helsinki. CSF samples were collected from
prodromal patients meeting criteria for initial prodromal state of
psychosis (IPS) (n = 24) as described previously [10,21], drug-naı¨ve
patients diagnosed with first-onset paranoid schizophrenia or brief
psychotic disorder due to duration of illness (DSM-IV 295.30,
n = 54) and from demographically matched healthy volunteers
(n = 70) (Table 1).
All samples were collected in a standardized fashion by the same
team of experienced clinicians using a non-traumatic lumbar
puncture procedure [22]. Trained clinical psychiatrists performed
clinical assessments. Glucose levels in CSF and serum from healthy
subjects, IPS and schizophrenic patients were measured immediately
after collection using a NOVA BioProfile analyzer (Nova Bio-
medical, Waltham, USA). CSF samples were divided into aliquots
and stored at 280uC. None of the samples underwent more than 2
freeze-thaw cycles prior to experiments. All experiments were
performed under blind and randomized conditions.
Diagnosis and inclusion/exclusion criteria for initial
prodromal patients
Patients diagnosed with an IPS (n = 24) had sought help for mental
health problems at the Cologne Early Recognition and In-
tervention Centre (FETZ), University of Cologne, and had been
admitted to hospital for diagnostic reasons. An IPS was assumed if
one or more of ten basic cognitive-perceptive symptoms was
present, which were found to be highly predictive of schizophrenia
in an earlier prospective study [4]. Or, in line with the so-called
‘UHR’ criteria [6], if attenuated (APS) or transient psychotic
symptoms were present. The UHR criteria, aiming to detect
imminent risk of psychosis, have shown an average 12-month
conversion rate of 38.2% in non-treated prodromal subjects
predominantly with APS [6,11,23–26]. The ten basic symptoms
were included as an extension to these UHR criteria to identify an
even earlier state of the initial prodrome. A prospective study has
shown that 20% of patients presenting with one or more of the ten
basic symptoms had developed schizophrenia within the first year,
an additional 17% in the second, 13% in the third, and 15%
within 4 to 14 years after first examination [4,5].
Inclusion criteria for an IPS were: (i) One or more of the
following basic symptoms with a score of 3 or more on the SPI-A
[27] which had first presented at least one year ago: thought
interferences; thought perseveration; thought pressure; thought
blockages; disturbances of receptive language, either heard or
read; decreased ability to discriminate between ideas and
perception, fantasy and true memories; unstable ideas of reference;
derealization; visual and/or acoustic perception disturbances; (ii)
one or more of the following APS with a score of 3 to 5 on SOPS
[10] within the last three months, appearing several times per week
for a period of at least one week and, with the same severity, for no
longer than one year: ideas of reference; odd beliefs or magical
thinking; unusual perceptual experiences; odd thinking and
speech; suspiciousness or paranoid ideation; (iii) one or more of
the following brief limited intermittent psychotic symptoms with
a PANSS score of at least 4 [6] for less than one week and an
interval between episodes at least one week, resolving spontane-
ously: hallucinations; delusions; formal thought disorder; gross
disorganized or catatonic behaviour.
Exclusion criteria for an IPS were: (i) present or past psychotic
episode; (ii) current substance abuse or dependence; (iii) neurological,
cerebral or other somatic illness that may account for the symptoms;
(iv) mental retardation, and (v) age below 18 or above 40 years.
Prodromal symptoms were assessed by trained interviewers
using the Structured Interview for the Scale of Prodromal
Syndromes (SIPS/SOPS [28]), the Positive and Negative Syn-
drome Scale (PANSS [21]) and the Schizophrenia Proneness
Instrument-Adult version (SPI-A [27]). The SIPS/SOPS had
a pair-wise interrater concordance of 77% between four raters, the
PANSS 82%, and the SPI-A had a concordance rate with an
expert rating of 92%. The German version of the Structured
Clinical Interview for DSM-IV [29] was administered to ascertain
exclusion criteria disorders.
Altogether 7 (29.1%) of the IPS patients have meanwhile made
the transition to overt psychosis, 4 to schizophrenia, paranoid
subtype, 1 to schizophrenia, undifferentiated subtype, 1 to schizo-
affective disorder and 1 to delusional disorder. The mean time
from baseline assessment to transition was 14.365.3 months. All
not yet converted patients were followed up for at least three years.
1H-NMR Spectroscopy of CSF Samples
The volume of CSF samples (150 ml) was made up to a final
volume of 500 ml by the addition of D2O in preparation for 1H-
NMR spectroscopic analysis. Standard 1-D 600 MHz 1H-NMR
spectra were acquired for all samples using a pre-saturation pulse
sequence to effect suppression of the water resonance (pulse
sequence: relaxation delay-90u-t1-90u-tm-90u-acquire FID; Bruker
Analytische GmbH, Rheinstetten, Germany). In this pulse
sequence, a secondary radio frequency irradiation is applied
specifically at the water resonance frequency during the relaxation
delay of 2s and the mixing period (tm = 100 ms), with t1 fixed at
3 ms. Typically 256 transients were acquired at 300K into 32K
data points, with a spectral width of 6000Hz and an acquisition
time of 1.36s per scan. Prior to Fourier transformation, the free
induction decays were multiplied by an exponential weight
function corresponding to a line-broadening factor of 0.3 Hz.
Preparation of CSF Samples for SELDI Analysis
5 ml of each CSF sample was applied to protein chips with
different chemical properties at various pH conditions. The best
condition was chosen at pH9.0 on strong anion exchanger Q10
chip, based on number and separation of peaks resolved. Briefly,
the array spots were pre-activated twice with binding buffer
(100mM Tris-HCl, pH 9.0) at room temperature for 10 min on
a shaker (frequency = 600 rpm). 50 ml binding buffer was added
into each spot prior to the addition of 5 ml CSF sample. The
protein chips were incubated on a shaker for 60 min at room
temperature, then washed twice with binding buffer, once with
H2O, and air-dried. The chips were then sequentially treated
twice with 0.6 ml of a 100% saturated sinapinic acid (3, 5-
dimethoxy-4-hydroxycinnamic acid) in 50% acetonitrile and 0.5%
trifluoroacetic acid. The chips were analyzed with the Bio-Rad
ProteinChip Reader (Bio-Rad ProteinChip System Series 4000).
Each sample was analyzed twice to confirm reproducibility in
identifying the differentially expressed proteins and to ensure
stability of instrument performance.
SELDI-TOF-MS Analysis
The arrays were analyzed with the Bio-Rad ProteinChip System
Series 4000 (Bio-Rad, USA). Mass spectra of proteins were
Profiling Prodromal Psychosis
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generated by using an average of 254 laser shots at a laser intensity
of 2000 (nJ). For data acquisition, the detection size range was
between 2.5 and 200 kDa. The laser was focused at 10 kDa. The
mass-to-charge ratio (m/z) of each of the proteins captured on the
array surface was determined relative to external calibration
standards (Bio-Rad; USA): bovine insulin (5,733.6 Da), human
ubiquitin (8,564.8 Da), bovine cytochrome c (12,230.9 Da), bovine
superoxide dismutase (15,591.4 Da), horseradish peroxidase
(43,240 Da) and BSA (66,410 Da). The data were analyzed with
PROTEINCHIP data analysis software version 3.0 and Cipher-
gen Express Software 3.0 (Bio-Rad; USA). Matrix attenuation was
set at 2,500Da and shot sequence was set with one warming shot at
2000 (nJ) followed by 4 data shot at 1800 (nJ). The Ciphergen
Express Software 3.0 was used to compile all spectra and
autodetect quantified mass peaks within a mass range between
2,500–200,000 Da and signal to noise threshold was set at 5. Peak
labelling was completed by using second-pass peak selection with
0.2% of the mass window, and estimated peaks were added. The
peak information of all spectra was exported for further statistic
analyses.
Data Reduction and Pattern Recognition Procedures
To efficiently evaluate the metabolic variability within and
between biofluids derived from patients and controls, spectra
were data reduced using the software program AMIX (Analysis of
MIXtures version 2.5, Bruker Rheinstetten, Germany) and
exported into SIMCA-P (Version 11.0, Umetrics AB, Umea˚,
Sweden) where a range of multivariate statistical analyses were
conducted. For proteomic studies, the readings from each peak
with S/N.5 were output and exported into SIMCA-P for further
analysis. Initially principal components analysis was applied to the
data in order to discern the presence of inherent similarities in
spectral profiles. Where the classification of 1H-NMR spectra was
influenced by exogenous contaminants, the spectral regions
containing those signals were removed from statistical analysis.
In order to confirm the biomarkers differentiating between the
schizophrenia patients and matched controls, projection to PLS-
DA was employed.
SUPPORTING INFORMATION
Figure S1 Proteomic analysis of CSF samples from patients with
prodromal schizophrenia, and depression patients. (A) and (B)
PLS-DA scores plots showing a degree of separation of prodromal
schizophrenia patients (&) from depression patients ($) as
determined by the SELDI CSF spectra. The key changing
proteomic peaks are from secretogranin II (529-566) and two
transthyretin isoforms.
Found at: doi:10.1371/journal.pone.0000756.s001 (0.99 MB
DOC)
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